KBP Sells Hypertension Candidate for $1.3 Billion to Novo Nordisk

KBP Biosciences sold global rights to its late-stage candidate for uncontrolled hypertension to Denmark’s Novo Nordisk in an agreement worth up to $1.3 billion. The drug, ocedurenone, is an oral, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA) currently in a US, EU and Asia Phase III trial in patients with uncontrolled hypertension and advanced chronic kidney disease (CKD). KBP Biosciences is a global biotech now headquartered in Singapore, though its initial home was in Jinan, China, where it continues to have operations along with Shanghai and Princeton, NJ. More details....